title: The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.
abstract: The International Staging System (ISS) is the most important prognostic system for multiple myeloma (MM). It was identified in the era of conventional agents. The outcome of MM has significantly changed by novel agents. Thus the applicability of ISS system in the era of novel agents in Chinese patients needs to be demonstrated. We retrospectively analyzed the clinical outcomes and prognostic significance of ISS system in 1016 patients with newly diagnosed multiple myeloma in Chinese patients between 2008 and 2012, who received bortezomib- or thalidomide-based regimens as first-line therapy. The median overall survival (OS) of patients for ISS stages I/II/III was not reached/55.4 months/41.7 months (p < 0.001), and the median progression-free survival (PFS) was 30/29.5/25 months (p = 0.072), respectively. Statistically significant difference in survival was confirmed among three ISS stages in thalidomide-based group, but not between ISS stages I and II in bortezomib-based group. These findings suggest that ISS system can predict the survival in the era of novel agents in Chinese MM patients, and bortezomib may have the potential to partially overcome adverse effect of risk factors on survival, especially in higher stage of ISS system.
authors.affiliation: Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Lu
authors.affiliation: Peking University People's Hospital and Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing 100044, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, 8 Workers Stadium South Road, Beijing 100020, China.
authors.forename: Aijun
authors.initials: A
authors.lastname: Liu
authors.affiliation: Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
authors.forename: Weijun
authors.initials: W
authors.lastname: Fu
authors.affiliation: Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Du
authors.affiliation: Peking University People's Hospital and Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing 100044, China.
authors.forename: Xiaojun
authors.initials: X
authors.lastname: Huang
authors.affiliation: Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, 8 Workers Stadium South Road, Beijing 100020, China.
authors.forename: Wenming
authors.initials: W
authors.lastname: Chen
authors.affiliation: Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Hou
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use*; D002681:China; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D012189:Retrospective Studies; D016019:Survival Analysis; D013792:Thalidomide / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000069286:Bortezomib